Lasers can reduce retinal thickening

Article

Among diabetic macular oedema (DME) patients, those with diffuse retinal thickening (DRT) experience greater reductions in retinal thickening after undergoing focal laser photocoagulation when compared with either cystoid macular oedema (CME) or vitreomacular interface abnormalities (VMIA) patients, according to a study published online ahead of print by the British Journal of Ophthalmology.

Among diabetic macular oedema (DME) patients, those with diffuse retinal thickening (DRT) experience greater reductions in retinal thickening after undergoing focal laser photocoagulation when compared with either cystoid macular oedema (CME) or vitreomacular interface abnormalities (VMIA) patients, according to a study published online ahead of print by the British Journal of Ophthalmology.

Na Rae Kim of Inha University Hospital, the Republic of Korea, and colleagues examined 70 eyes, all undergoing laser photocoagulation for significant macular oedema, to identify if optical coherence tomography (OCT) patterns could predict visual outcome in these patients. Based on features of the preoperative macular OCT images, examined retrospectively, patients were classified into four categories: DRT, CME, serous retinal detachment (SRD) and VMIA. The team compared retinal thickness and volume and visual acuity (VA) pre- and postoperatively for each of the four groups.

For the different OCT types, the researchers found a statistically significant difference in retinal changes: p=0.002 for retinal thickness and p

The researchers therefore concluded that, because of these differences in response between the groups, using OCT to gain accurate preoperative classification of the grade of DME will allow for greater predictability of outcome.

Recent Videos
(Image credit: Ophthalmology Times Europe) AGS 2025: Clemens Strohmaier, PhD, on improving aqueous humour outflow following excimer laser trabeculostomy
3 experts are featured in this series.
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
3 experts are featured in this series.
3 experts are featured in this series.
Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis, talks about how her research at the Glaucoma 360 symposium
I. Paul Singh, MD, an anterior segment and glaucoma specialist, discusses the Glaucoma 360 conference, where he participated in a panel discussion on the use of artificial intelligence (AI) in glaucoma care.
Sunita Radhakrishnan, MD, an associate at the Glaucoma Center of San Francisco, speaks at the annual Glaucoma 360 meeting about electrical neurostimulation.
3 experts are featured in this series.
3 experts are featured in this series.
Related Content
© 2025 MJH Life Sciences

All rights reserved.